Frontier Clinical Research, LLC

Smithfield, Pennsylvania 15478

5 studies enrolling now · 32 studies all time

What they study most

Acute Migraine, Acute Pain, Atherosclerotic Cardiovascular Disease, Back Muscle Spasm, Back Pain, Back Spasm Upper, Back Strain, COVID-19, Covid19, Diabetes Mellitus, Diabetes Mellitus, Type 2, Episodic Migraine

Studies at this site

• A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine — Recruiting now
• A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine — Recruiting now
• A Study to Learn About the Safety, Tolerability, and Immunogenicity of a Fifth Dose of 6-Valent OspA-Based Lyme Disease Vaccine — Recruiting now
• A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes — Running, not enrolling
• A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients. — Running, not enrolling
• A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity — Running, not enrolling
• A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes — Starting soon
• Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease — Running, not enrolling
• A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine — Stopped early
• An Efficacy, Safety, Tolerability, Immunogenicity, and Lot-Consistency Clinical Trial of a 6-Valent OspA-Based Lyme Disease Vaccine (VLA15) — Completed
• Safety Study of Tenapanor for the Treatment of Pediatric Patients (6 to Less Than 18 Years Old) With IBS-C — Enrolling by invitation
• Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patients 12 to Less Than 18 Years — Running, not enrolling
• A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes — Running, not enrolling
• A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine — Stopped early
• A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study of Elismetrep (K-304) in the Treatment of Migraine — Completed
• Benefits of Microcor in Ambulatory Decompensated Heart Failure — Completed
• Study of Obeldesivir in Nonhospitalized Participants With COVID-19 — Completed
• The Prevent Severe COVID-19 (PRESECO) Study — Completed
• JINZHEN for Treatment of Mild to Moderate COVID-19 — Completed
• A Study of LY3437943 in Participants With Type 2 Diabetes — Completed
• Assessment In a Real World Setting of the Effect of Inhaled Steroid-based Triple Therapy Versus the Combination of Tiotropium and Olodaterol on Reducing Chronic Obstructive Pulmonary Disease (COPD) Exacerbations [AIRWISE] — Completed
• Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine — Completed
• Efficacy and Safety of Tolperisone in Subjects With Pain Due to Acute Back Muscle Spasm — Completed
• A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Study 03 — Stopped early
• A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Study 04 — Stopped early
• Study to Evaluate the Safety and Efficacy of Relamorelin in Participants With Diabetic Gastroparesis Study 02 — Stopped early
• 12-Week Placebo-controlled Study of Atogepant for the Preventive Treatment of Migraine in Participants With Episodic Migraine — Completed
• Study to Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine — Completed
• A Study to Examine the Safety and Efficacy of a New Drug in Patients With Symptoms of Overactive Bladder (OAB) — Completed
• A Clinical Trial of KT07 Capsule in the U.S.A — Completed
• BioFe, Medical Food for the Dietary Management of Iron Deficiency — Completed
• Evaluating the Use of Oseltamivir for the Treatment of Influenza in Adults — Completed